title: Novel targeted therapies for eosinophil-associated diseases and allergy.
abstract: Eosinophil-associated diseases often present with life-threatening manifestations and/or chronic organ damage. Currently available therapeutic options are limited to a few drugs that often have to be prescribed on a lifelong basis to keep eosinophil counts under control. In the past 10 years, treatment options and outcomes in patients with clonal eosinophilic and other eosinophilic disorders have improved substantially. Several new targeted therapies have emerged, addressing different aspects of eosinophil expansion and inflammation. In this review, we discuss available and currently tested agents as well as new strategies and drug targets relevant to both primary and secondary eosinophilic diseases, including allergic disorders.
authors.affiliation: Institute of Pharmacology, University of Bern, CH-3010 Bern, Switzerland; email: hus@pki.unibe.ch.
authors.forename: Susanne
authors.initials: S
authors.lastname: Radonjic-Hoesli
authors.forename: Peter
authors.initials: P
authors.lastname: Valent
authors.forename: Amy D
authors.initials: AD
authors.lastname: Klion
authors.forename: Michael E
authors.initials: ME
authors.lastname: Wechsler
authors.forename: Hans-Uwe
authors.initials: HU
authors.lastname: Simon
mesh_terms: D000818:Animals; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D055808:Drug Discovery / Q000379:methods*; D004802:Eosinophilia / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D004804:Eosinophils / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D058990:Molecular Targeted Therapy; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D018926:Anti-Allergic Agents
keywords: asthma; biologicals; chronic eosinophilic leukemia; hypereosinophilic syndrome; tyrosine kinase inhibitors